Natural history and impact of treatment with tafamidis on major cardiovascular outcome‐free survival time in a cohort of patients with transthyretin amyloidosis

Archive ouverte

Bézard, Mélanie | Kharoubi, Mounira | Galat, Arnault | Poullot, Elsa | Guendouz, Soulef | Fanen, Pascale | Funalot, Benoit | Moktefi, Anissa | Lefaucheur, Jean‐pascal | Abulizi, Mukedaisi | Deux, Jean‐françois | Gendre, Thierry | Audard, Vincent | Karoui, Khalil | Canoui‐poitrine, Florence | Zaroui, Amira | Itti, Emmanuel | Teiger, Emmanuel | Planté‐bordeneuve, Violaine | Oghina, Silvia | Damy, Thibaud

Edité par CCSD ; European Society of Cardiology (Wiley) -

International audience. Hereditary (ATTRv) and wild-type (ATTRwt) transthyretin amyloidosis are severe and fatal systemic diseases, characterised by amyloid fibrillar accumulation principally in the heart or peripheral nerves (or both). Since 2012, tafamidis has been used in France to treat patients with ATTRv with neuropathy (alone or combined with cardiomyopathy). Recently, the Phase III ATTRACT trial showed that tafamidis decreased the relative risk of mortality in ATTR amyloidosis with cardiomyopathy. The aims of this study were to assess the clinical characteristics of ATTR amyloidosis in a real-life population in comparison to the population included in the ATTRACT trial and to assess the impact of tafamidis treatment on major cardiovascular outcome (MCO)-free survival time without cardiac decompensation, heart transplant, or death.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion